2023年ESMO大会将于10月20日-24日在西班牙马德里举行，大会涵盖了肿瘤领域的基础研究、转化研究以及最新的临床研究进展，为临床实践、多学科讨论等提供广阔、卓越的学术平台。
近日，ESMO官网公布了除LBA外的摘要标题。本期小编整理本次批露的肺癌领域重磅研究（主要包含MO：mini oral；O：oral）标题，以飨读者。
免疫治疗
1261O - Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase 3 CheckMate 816 trial
Ⅲ期CheckMate 816：新辅助纳武利尤单抗+伊匹木单抗 vs. 化疗治疗NSCLC
Speakers：Mark M. Awad (Boston, United States of America)
1264MO - IMpower010: exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
IMpower010研究：通过TGFβ癌相关成纤维细胞基因特征表达对接受阿替利珠单抗或最佳支持治疗的可切除NSCLC患者的无病生存期进行探索性分析
Speakers：Nasser K. Altorki (New York, United States of America)
1292MO - A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A
NEJ039A研究：放化疗后应用度伐利由单抗治疗PS 2或老年（≥ 75岁）不可切除III期NSCLC患者的II期研究：
Speakers：Ryo Ko (Shizuoka, Japan)
1293MO - Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy – interim results from the TRADE-hypo trial
TRADE-低分割试验的中期结果：低分割和常规分割胸部放疗联合度伐利尤单抗治疗不适合化疗的老年或体弱III期NSCLC患者的安全性和有效性
Speakers：Farastuk Bozorgmehr (Heidelberg, Germany)
1989MO - Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): the Phase 1/2 LUPER study
在复发SCLC中，卢比替定联合帕博利珠单抗的1/2期LUPER研究
Speakers：Antonio Calles Blanco (Madrid, Spain)
ADC治疗
1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
TROPION-Lung05：datopotamab deruxtecan（Dato-DXd）治疗既往经治的具有可靶向基因组改变（AGA）的NSCLC
Speakers：Luis Paz-Ares (Madrid, Spain)
1319MO - Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01
HERTHENA-Lung01：HER3-DXd治疗既往经治的晚期EGFR突变NSCLC的颅内活性
Speakers：Melissa L. Johnson (Nashville, United States of America)
1320MO - Phase II trial of amivantamab plus lazertinib in patients with EGFR-mutant lung cancers with leptomeningeal metastases
埃万妥单抗+拉泽替尼治疗EGFR突变伴脑膜转移肺癌的Ⅱ期研究
Speakers：Helena A. Yu (New York, United States of America)
1321MO - Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2 (ERBB2)-Mutant (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC) With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-Lung01 and DESTINY-Lung02
DESTINY-Lung01和DESTINY-Lung02汇总分析：德曲妥珠单抗（T-DXd）治疗HER2（ERBB2）突变（HER2m）伴/不伴脑转移的转移性NSCLC
Speakers：David Planchard (Villejuif, Cedex, France)
1990MO - Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial
Ⅱ期TROPiCS-03篮子试验的初步结果：戈沙妥珠单抗二线治疗ES-SCLC
Speakers：Afshin Dowlati (Cleveland, United States of America)
双特异性抗体/新型疗法/其他
1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
靶向PD-1和TIM-3的双特异性抗体AZD7789治疗既往经抗PD-（L）1治疗的ⅢB-Ⅳ期NSCLC的安全性和初步疗效
Speakers：Benjamin Besse (Villejuif, France)
1315MO - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
HER2×HER3双特异性抗体zenocutuzumab治疗晚期NRG1融合阳性（NRG1+）NSCLC的持久疗效Speakers：Alison Schram (New York, United States of America)
1316MO-BL-B01D1,a first-in-class EGFRxHER3 bispecific antibody-drug conjugate,in patients with Non-Small Cell Lung Cancer:Updated results from first-in-human phase 1 study
BL-B01D1（首创的EGFR×HER3双特异性抗体-药物偶联物）用于非小细胞肺癌患者：第一项人体1期研究的更新结果
Speakers：Li Zhang (Guangzhou, China)
1318MO - First-in-Human Study of ABBV-637, an EGFR-targeting BCL-XL–Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (OSI) in Relapsed/Refractory, EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
ABBV-637（一种EGFR靶向BCL-XL抑制性抗体-药物偶联物）联合奥希替尼（OSI）治疗复发性/难治性EGFR突变非小细胞肺癌（NSCLC）的首次人体研究Speakers：Julia K. Rotow (Boston, United States of America)
1312MO - Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II)
Ⅱ期TACTI-002：抗原呈递细胞激动剂eftilagimod alpha（可溶性LAG-3）+帕博利珠单抗一线治疗NSCLC队列的OS数据
Speakers：Enric Carcereny (Badalona, Spain)
1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
Pelcitoclax（APG-1252）联合奥希替尼治疗EGFR突变型非小细胞肺癌（NSCLC）患者的最新结果
Speaker
Yuxiang Ma (Guangzhou, China)
1262MO - Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial
在III期IFCT-0302试验中，最小随访与基于CT扫描的随访对完全切除NSCLC患者报告结局的影响
Speakers：Guillaume Eberst (Besancon, France)
1263MO - The Impact of PET-CT and Brain MRI for Metastasis Detection among Patients with T1-Stage Lung Cancer: Findings from a Large Cohort Study
PET-CT和脑部MRI对T1期肺癌患者转移灶检测的影响：一项大型队列研究的结果
Speakers：Wenhua Liang (Guangzhou, China)
1291O -Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label, randomised, controlled trial.
在不可手术的III期非小细胞肺癌患者中，基于42 Gy放化疗的FDG-PET，放疗加强至74Gy（RTEP 7- IFCT 1401）：一项前瞻性、多中心、开放标签、随机对照试验
Speakers：Pierre Vera (Rouen, France)
2023ESMO.https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/list?r=pt%7E61_62_7_31
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
